HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jean-Charles Fruchart Selected Research

Triglycerides (Triacylglycerol)

1/2021Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
1/2020Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.
12/2019SPPARM alpha: the Lazarus effect.
1/2019The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
12/2018Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
10/2017Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
10/2009Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
11/2008The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
11/2008The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
8/2008Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jean-Charles Fruchart Research Topics

Disease

36Atherosclerosis
01/2019 - 05/2002
22Type 2 Diabetes Mellitus (MODY)
01/2020 - 05/2004
20Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 05/2003
18Coronary Disease (Coronary Heart Disease)
09/2007 - 07/2002
15Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2021 - 08/2004
15Dyslipidemias (Dyslipidemia)
01/2020 - 08/2003
14Inflammation (Inflammations)
01/2020 - 01/2002
10Insulin Resistance
08/2007 - 08/2003
9Hypertriglyceridemia
12/2018 - 12/2002
7Myocardial Infarction
09/2007 - 09/2002
6Obesity
05/2013 - 08/2005
6Stroke (Strokes)
09/2007 - 07/2003
5Hypertension (High Blood Pressure)
05/2007 - 08/2002
4Hepatocellular Carcinoma (Hepatoma)
11/2004 - 12/2002
3Heart Failure
12/2018 - 06/2007
3Hyperlipidemias (Hyperlipidemia)
08/2007 - 08/2005
3Coronary Artery Disease (Coronary Atherosclerosis)
05/2006 - 12/2002
3Atherosclerotic Plaque (Atheroma)
01/2006 - 03/2004
3Hepatoblastoma
08/2003 - 04/2002
2Alcoholic Fatty Liver
01/2022 - 01/2020
2Chronic Renal Insufficiency
01/2020 - 04/2006
2Thrombosis (Thrombus)
12/2018 - 02/2007
2Acute Coronary Syndrome
01/2011 - 04/2005
2Heart Arrest (Cardiac Arrest)
09/2007 - 04/2005
2Angina Pectoris
09/2003 - 08/2002
1Non-alcoholic Fatty Liver Disease
01/2020
1Fibrosis (Cirrhosis)
01/2020
1Diabetic Retinopathy (Retinopathy, Diabetic)
12/2018
1Peripheral Arterial Disease
12/2018
1Drug-Related Side Effects and Adverse Reactions
01/2016
1Abdominal Obesity
10/2009
1Systemic Vasculitis
12/2007
1Pathologic Complete Response
12/2007
1Muscular Diseases (Myopathy)
08/2007
1Rhabdomyolysis
08/2007

Drug/Important Bio-Agent (IBA)

29LipidsIBA
01/2020 - 01/2002
27Triglycerides (Triacylglycerol)IBA
01/2021 - 08/2002
23PPAR alphaIBA
01/2021 - 09/2002
18HDL CholesterolIBA
01/2021 - 07/2002
17LDL CholesterolIBA
01/2020 - 08/2002
16Lipoproteins (Lipoprotein)IBA
12/2019 - 06/2002
15Peroxisome Proliferator-Activated Receptors (PPAR)IBA
08/2007 - 01/2002
14oxidized low density lipoproteinIBA
12/2018 - 05/2002
14Glucose (Dextrose)FDA LinkGeneric
10/2009 - 09/2002
12LigandsIBA
08/2008 - 12/2002
11CholesterolIBA
08/2008 - 09/2002
10ApolipoproteinsIBA
11/2008 - 07/2003
9Fibric Acids (Fibrates)IBA
05/2013 - 12/2002
9LDL Lipoproteins (beta Lipoproteins)IBA
11/2008 - 08/2002
7Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
10/2017 - 04/2004
7Fenofibrate (CiL)FDA LinkGeneric
01/2016 - 12/2002
7PPAR gammaIBA
08/2007 - 09/2003
6(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
01/2022 - 10/2017
6Apolipoprotein A-I (Apolipoprotein A1)IBA
12/2007 - 04/2002
6ThiazolidinedionesIBA
08/2007 - 08/2003
6Messenger RNA (mRNA)IBA
06/2007 - 02/2003
5Insulin (Novolin)FDA Link
01/2019 - 05/2004
5HDL LipoproteinsIBA
11/2008 - 07/2002
5Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
07/2007 - 09/2003
4Atorvastatin (Lipitor)FDA Link
11/2006 - 04/2005
3Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
01/2020 - 07/2003
3Biomarkers (Surrogate Marker)IBA
12/2018 - 06/2004
3Apolipoproteins E (ApoE)IBA
04/2009 - 06/2005
3Apolipoprotein A-VIBA
08/2008 - 01/2007
3Liver X ReceptorsIBA
08/2008 - 04/2003
3C-Reactive ProteinIBA
12/2007 - 07/2003
3Trinitrotoluene (TNT)IBA
11/2006 - 06/2006
3Interleukin-6 (Interleukin 6)IBA
05/2006 - 07/2003
3GW 4064IBA
04/2006 - 02/2003
3AntioxidantsIBA
05/2005 - 07/2003
3Chenodeoxycholic Acid (Chenix)FDA Link
11/2004 - 02/2003
2Apolipoprotein E2IBA
08/2008 - 12/2006
2Aryldialkylphosphatase (Paraoxonase)IBA
12/2007 - 05/2004
2HomocysteineIBA
08/2007 - 06/2004
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2007 - 05/2006
2Proteins (Proteins, Gene)FDA Link
05/2007 - 06/2003
2Fibrinogen (Factor I)FDA Link
05/2006 - 07/2003
2Gemfibrozil (Lopid)FDA LinkGeneric
01/2006 - 12/2002
2MelatoninIBA
09/2005 - 05/2002
2Transcription Factors (Transcription Factor)IBA
08/2005 - 09/2002
2IDL Lipoproteins (Lipoprotein, IDL)IBA
06/2005 - 06/2004
2VLDL LipoproteinsIBA
06/2005 - 06/2004
2PolyphenolsIBA
12/2004 - 03/2003
2Lipoprotein(a)IBA
06/2004 - 08/2002
2EnzymesIBA
05/2004 - 07/2003
2Bile Acids and Salts (Bile Acids)IBA
04/2004 - 04/2002
2Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
09/2003 - 07/2003
16- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
01/2022
1Sodium-Glucose Transport ProteinsIBA
01/2022
1Cell Adhesion MoleculesIBA
01/2020
1Antigen-Antibody Complex (Immune Complex)IBA
12/2007
1Anticardiolipin AntibodiesIBA
12/2007
1AntibodiesIBA
12/2007
1Apolipoproteins AIBA
08/2007
1CreatinineIBA
08/2007

Therapy/Procedure

9Therapeutics
10/2017 - 06/2004
3Secondary Prevention
12/2018 - 12/2002
2Drug Therapy (Chemotherapy)
11/2008 - 06/2004
2Resuscitation
09/2007 - 04/2005
1Aftercare (After-Treatment)
12/2018